IDH2 and central nervous system cancer: When identical analyses were performed in IDH-wildtype glioblastoma patients (entire patients with LM [n = 179], initial LM [n = 82], and recurrent LM [n = 97]), a similar trend of results to that of entire glioma patients was observed.